NOVOCURE LTD (NVCR) Stock Fundamental Analysis

NASDAQ:NVCR • JE00BYSS4X48

11.365 USD
-0.03 (-0.22%)
Last: Feb 20, 2026, 03:57 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

NVCR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NVCR have multiple concerns. While showing a medium growth rate, NVCR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year NVCR has reported negative net income.
  • In the past year NVCR has reported a negative cash flow from operations.
  • NVCR had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: NVCR reported negative operating cash flow in multiple years.
NVCR Yearly Net Income VS EBIT VS OCF VS FCFNVCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

  • NVCR has a Return On Assets (-13.05%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -52.05%, NVCR is in line with its industry, outperforming 50.27% of the companies in the same industry.
Industry RankSector Rank
ROA -13.05%
ROE -52.05%
ROIC N/A
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
NVCR Yearly ROA, ROE, ROICNVCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • NVCR has a Gross Margin of 75.57%. This is amongst the best in the industry. NVCR outperforms 87.03% of its industry peers.
  • NVCR's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NVCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
NVCR Yearly Profit, Operating, Gross MarginsNVCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NVCR has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NVCR has been increased compared to 5 years ago.
  • NVCR has a worse debt/assets ratio than last year.
NVCR Yearly Shares OutstandingNVCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NVCR Yearly Total Debt VS Total AssetsNVCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • NVCR has an Altman-Z score of -0.13. This is a bad value and indicates that NVCR is not financially healthy and even has some risk of bankruptcy.
  • NVCR has a Altman-Z score of -0.13. This is comparable to the rest of the industry: NVCR outperforms 47.57% of its industry peers.
  • A Debt/Equity ratio of 2.21 is on the high side and indicates that NVCR has dependencies on debt financing.
  • NVCR has a Debt to Equity ratio of 2.21. This is amonst the worse of the industry: NVCR underperforms 82.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.21
Debt/FCF N/A
Altman-Z -0.13
ROIC/WACCN/A
WACC8.62%
NVCR Yearly LT Debt VS Equity VS FCFNVCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • NVCR has a Current Ratio of 1.55. This is a normal value and indicates that NVCR is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.55, NVCR is not doing good in the industry: 72.97% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.50 indicates that NVCR should not have too much problems paying its short term obligations.
  • NVCR's Quick ratio of 1.50 is in line compared to the rest of the industry. NVCR outperforms 42.70% of its industry peers.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.5
NVCR Yearly Current Assets VS Current LiabilitesNVCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for NVCR have decreased strongly by -15.00% in the last year.
  • The Revenue has grown by 11.17% in the past year. This is quite good.
  • Measured over the past years, NVCR shows a quite strong growth in Revenue. The Revenue has been growing by 11.49% on average per year.
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
Revenue 1Y (TTM)11.17%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%7.81%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.91% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 18.14% on average over the next years. This is quite good.
EPS Next Y8.74%
EPS Next 2Y0.77%
EPS Next 3Y8.15%
EPS Next 5Y21.91%
Revenue Next Year9.59%
Revenue Next 2Y7.45%
Revenue Next 3Y8.34%
Revenue Next 5Y18.14%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NVCR Yearly Revenue VS EstimatesNVCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
NVCR Yearly EPS VS EstimatesNVCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NVCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NVCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCR Price Earnings VS Forward Price EarningsNVCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCR Per share dataNVCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.77%
EPS Next 3Y8.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NVCR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVOCURE LTD

NASDAQ:NVCR (2/20/2026, 3:57:02 PM)

11.365

-0.03 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30
Earnings (Next)02-26
Inst Owners83.68%
Inst Owner Change4.94%
Ins Owners2.76%
Ins Owner Change0.22%
Market Cap1.27B
Revenue(TTM)642.27M
Net Income(TTM)-177.65M
Analysts81.54
Price Target24.55 (116.01%)
Short Float %7.91%
Short Ratio4.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.64%
Min EPS beat(2)8.12%
Max EPS beat(2)23.15%
EPS beat(4)3
Avg EPS beat(4)-2.03%
Min EPS beat(4)-73.92%
Max EPS beat(4)34.54%
EPS beat(8)7
Avg EPS beat(8)8.46%
EPS beat(12)8
Avg EPS beat(12)0.73%
EPS beat(16)10
Avg EPS beat(16)-6.5%
Revenue beat(2)2
Avg Revenue beat(2)1.97%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.98%
Revenue beat(4)4
Avg Revenue beat(4)1.94%
Min Revenue beat(4)0.18%
Max Revenue beat(4)3.65%
Revenue beat(8)7
Avg Revenue beat(8)3.15%
Revenue beat(12)7
Avg Revenue beat(12)1.16%
Revenue beat(16)9
Avg Revenue beat(16)0.67%
PT rev (1m)-2.88%
PT rev (3m)-10.64%
EPS NQ rev (1m)-3.34%
EPS NQ rev (3m)-4.84%
EPS NY rev (1m)-0.87%
EPS NY rev (3m)0.54%
Revenue NQ rev (1m)2.87%
Revenue NQ rev (3m)2.62%
Revenue NY rev (1m)0.87%
Revenue NY rev (3m)1.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.98
P/FCF N/A
P/OCF N/A
P/B 3.73
P/tB 3.73
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.74
BVpS3.05
TBVpS3.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.05%
ROE -52.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.57%
FCFM N/A
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 226.76%
Cap/Sales 4.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.5
Altman-Z -0.13
F-Score2
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)276.52%
Cap/Depr(5y)245.8%
Cap/Sales(3y)5.46%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
EPS Next Y8.74%
EPS Next 2Y0.77%
EPS Next 3Y8.15%
EPS Next 5Y21.91%
Revenue 1Y (TTM)11.17%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%7.81%
Revenue Next Year9.59%
Revenue Next 2Y7.45%
Revenue Next 3Y8.34%
Revenue Next 5Y18.14%
EBIT growth 1Y-10.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.92%
EBIT Next 3Y27.38%
EBIT Next 5Y42.57%
FCF growth 1Y26.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.83%
OCF growth 3YN/A
OCF growth 5YN/A

NOVOCURE LTD / NVCR FAQ

What is the fundamental rating for NVCR stock?

ChartMill assigns a fundamental rating of 2 / 10 to NVCR.


What is the valuation status of NOVOCURE LTD (NVCR) stock?

ChartMill assigns a valuation rating of 0 / 10 to NOVOCURE LTD (NVCR). This can be considered as Overvalued.


Can you provide the profitability details for NOVOCURE LTD?

NOVOCURE LTD (NVCR) has a profitability rating of 2 / 10.